Direkt zum Inhalt
Merck

F6432

FLT3 (571-993), active, GST tagged human

PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

Synonym(e):

CD135, FLK2, STK1

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

10 μG

€ 385,00

€ 385,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen

Über diesen Artikel

NACRES:
NA.32
UNSPSC Code:
51111800
Form:
buffered aqueous glycerol solution
Assay:
≥70% (SDS-PAGE)
Recombinant:
expressed in baculovirus infected Sf9 cells
Mol wt:
~73 kDa

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

recombinant

expressed in baculovirus infected Sf9 cells

Quality Level

product line

PRECISIO® Kinase

assay

≥70% (SDS-PAGE)

form

buffered aqueous glycerol solution

specific activity

60-81 nmol/min·mg

mol wt

~73 kDa

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... FLT3(2322)

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
SRP0349SRP5210F7930
recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

assay

≥70% (SDS-PAGE)

assay

≥80% (SDS-PAGE)

assay

≥70% (SDS-PAGE)

assay

≥70% (SDS-PAGE)

mol wt

~73 kDa

mol wt

54.2 kDa

mol wt

~85 kDa

mol wt

~73 kDa

form

buffered aqueous glycerol solution

form

aqueous solution

form

buffered aqueous glycerol solution

form

buffered aqueous glycerol solution

UniProt accession no.

P36888

UniProt accession no.

P36888

UniProt accession no.

-

UniProt accession no.

P22607

Gene Information

human ... FLT3(2322)

Gene Information

human ... FLT3(2322)

Gene Information

human ... FLT4(2324)

Gene Information

human ... FGFR3(2261)

General description

FLT3 (fms-related tyrosine kinase 3) is a tyrosine kinase receptor and the gene is localized to human chromosome 13q12. The encoded protein is composed of 993 amino acids, and consists of five immunoglobulin (Ig)-like domains in its exoplasmic region. It is also composed of a transmembrane region, a juxtamembrane domain, and two tyrosine kinase domains in its intracellular domain. The tyrosine kinase domains are linked via a kinase-insert domain.[1]

Biochem/physiol Actions

FLT3 (fms-related tyrosine kinase 3), upon interaction with its ligand, undergoes conformational changes to form homodimers. This results in phosphorylation and activation of downstream signaling pathways including phosphatidylinositol 3-kinase (PI3K/AKT), mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and signal transducer and activator of transcription 5 (STAT5) pathways.[2] Internal tandem duplication (ITD) mutation or a point mutation in juxtamembrane domain-coding region or within the activation loop domain, respectively, of this gene lead to its constitutive action. FLT3/ITD mutation is associated with later stages of acute myeloid leukemia (AML) pathogenesis. These patients have poor prognosis.[1]

Physical form

Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

Legal Information

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

Exclamation mark

Lagerklasse

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

signalword

Danger

Hazard Classifications

Aquatic Chronic 3 - ED ENV 1 - Eye Irrit. 2 - Skin Sens. 1


Zulassungslistungen

Zulassungslistungen werden hauptsächlich für chemische Produkte erstellt. Für nicht-chemische Produkte können hier nur begrenzte Angaben gemacht werden. Kein Eintrag bedeutet, dass keine der Komponenten gelistet ist. Es liegt in der Verantwortung des Benutzers, die sichere und legale Verwendung des Produkts zu gewährleisten.

9002-93-1

CAS No.

9002-93-1

CAS No.

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

D Gary Gilliland et al.
Current opinion in hematology, 9(4), 274-281 (2002-06-04)
FLT3 is the most frequently mutated gene in cases of acute myelogenous leukemia (AML). About 30 to 35% of patients have either internal tandem duplications (ITDs) in the juxtamembrane domain or mutations in the activating loop of FLT3. FLT3 mutations
J L Christensen et al.
Proceedings of the National Academy of Sciences of the United States of America, 98(25), 14541-14546 (2001-11-29)
Clonogenic multipotent mouse hematopoietic stem cells (HSCs) and progenitor cells are contained within the c-kit(+) (K) lineage(-/lo) (L) Sca-1(+) (S) population of hematopoietic cells; long-term (LT) and short-term (ST) HSCs are Thy-1.1(lo). c-kit is a member of the receptor tyrosine
Alexa S Green et al.
Science advances, 1(8), e1500221-e1500221 (2015-11-26)
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide short-term disease control, but relapse invariably occurs within months. Pim
D L Stirewalt et al.
Blood cancer journal, 4, e208-e208 (2014-05-03)
Patients with high FLT3 internal tandem duplication allelic ratios (FLT3/ITD-ARs) have a poor prognosis. Single-nucleotide polymorphism/comparative genomic hybridization, single-cell PCR and colony-forming assays were used to evaluate genotypic evolution of high FLT3/ITD-ARs in 85 acute myeloid leukemia (AML) patients. Microarrays
Yesid Alvarado et al.
Cancer, 120(14), 2142-2149 (2014-04-17)
FLT3-internal tandem duplication (ITD) mutations are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 inhibitors have shown clinical activity in AML with FLT3-ITD, but responses are usually short-lived. This study examined 69 FLT3-mutated patients with AML

Global Trade Item Number

SKUGTIN
F6432-10UG04061832850177

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung